Shire said it would buy Dyax for about $5.9 billion to gain access to the drug developer’s late-stage treatment for a severe breathing difficulty.
Shire said it would buy Dyax for about $5.9 billion to gain access to the drug developer’s late-stage treatment for a severe breathing difficulty.